Most sophisticated families have a continuity plan for the enterprise.
They think about ownership transfer, decision rights, liquidity, tax structure, key-person risk, governance, and who can step into a leadership role if something changes suddenly.
But there is a quieter question that is rarely handled with the same discipline:
What happens when the leader is still present, still competent, still working — but has less usable capacity than the role requires?
That is not a succession event in the traditional sense. It may not trigger disability insurance, a board resolution, or an emergency transition. Yet it can still alter the quality and speed of decisions across a company, a family, and sometimes an entire ecosystem of people who depend on one individual.
I think executive healthspan needs a new concept: biological continuity planning.
Not medical surveillance by the company. Not a family office collecting private lab values. Not an employer deciding what treatment someone should receive.
The opposite, actually.
A biological continuity plan keeps medical information private while making leadership continuity explicit.
The false choice between “healthy” and “unable to lead”
Most continuity plans are built around obvious discontinuities: death, severe illness, sudden incapacity, resignation, or retirement.
Real biology is usually less binary.
A leader can be functioning while gradually losing sleep quality, mobility, hearing, exercise capacity, pain tolerance, recovery speed, or cognitive endurance. None of those changes automatically means a person should stop working. Many are modifiable. Some are temporary. Some are clinically important; others are not.
The important point is that function exists on a continuum.
That idea is consistent with the World Health Organization’s healthy-aging framework, which emphasizes functional ability — what a person is actually able to be and do — rather than reducing health to the absence of diagnosis.
For executives and family-enterprise leaders, that distinction matters. The goal is not to create a medical score for leadership. It is to recognize that leadership is delivered through a biological system, and biological systems have variable capacity.
If the organization has no plan until incapacity is obvious, it has confused emergency succession with continuity.
Business continuity already understands redundancy
Outside medicine, continuity planning is not controversial.
The Federal Emergency Management Agency’s continuity guidance describes familiar concepts: identify essential functions, establish orders of succession, create delegations of authority, and make sure the organization can continue operating through disruption.
Those principles are designed for institutions, not human physiology. But the logic is useful.
If a function is mission-critical, you do not wait for failure to decide who can perform it.
If authority may need to transfer temporarily, you do not want the rules invented during the crisis.
If the institution depends on one person, you build redundancy before the person becomes unavailable.
Family-business research has been making a related point for decades: succession is a process, not a single event, and founder dependence, knowledge transfer, successor readiness, and governance all influence continuity.
What I think is missing is the bridge between these two worlds.
The Biological Continuity Plan
I would build that bridge around five questions.
1. What functions are truly leader-dependent?
Not every task performed by a founder or CEO is irreplaceable.
Some decisions are important because of title. Others are important because the leader carries unusual knowledge, relationships, judgment, or trust that has never been distributed.
A continuity review should identify the functions that would genuinely become fragile if the leader had less capacity for 30 days, 90 days, or a year.
That is a governance exercise, not a medical one.
2. Where is there no redundancy?
A company can have a succession chart and still have no operational redundancy.
Who can chair the meeting?
Who can make the capital-allocation decision?
Who can manage the critical relationship?
Who has access to the institutional memory that exists mostly in one person’s head?
Who can say “no” with legitimacy when the founder is temporarily unavailable?
The goal is not to replace the leader. It is to stop every small biological disruption from becoming an organizational disruption.
3. What capacity does the role actually require?
This is where executive health becomes relevant — privately.
A role may require frequent travel, long periods of concentration, high-quality judgment under uncertainty, public communication, physical presence, rapid recovery from time-zone changes, or the ability to sustain performance during high-stress periods.
Those demands should be understood because they determine what “fit for the role” means in practical terms.
The leader and clinician can then ask a private question:
What health factors most threaten the capacity this role requires?
That could involve cardiovascular risk, sleep apnea, chronic pain, mobility, hearing, vision, metabolic disease, medication burden, mental health, cancer screening, bone health, or something else entirely.
The family office does not need the answer.
The individual does.
4. What is the recovery protocol for temporary loss of capacity?
Continuity does not always mean succession.
Sometimes the right answer is temporary load reduction.
After surgery, illness, major travel, bereavement, or another physiologic stressor, a leader may benefit from a defined period in which decision load is reduced and selected responsibilities are delegated.
That should not require disclosing a diagnosis.
A pre-agreed protocol can simply say: when the leader voluntarily activates a recovery period, these decision rights transfer, these meetings are covered, these approvals are delegated, and responsibilities return through the agreed governance process, informed by the leader’s wishes and any applicable obligations.
That protects privacy and continuity at the same time.
5. What would trigger a governance conversation — without turning health into surveillance?
This is the most important boundary.
I do not think companies or family offices should monitor a leader’s wearable data, blood tests, biological-age score, medication list, or private medical record.
Health decisions belong to the individual and the clinician.
A continuity trigger should therefore be functional and voluntary, not diagnostic.
Examples might include the leader requesting temporary delegation, an extended inability to perform defined essential duties, or a previously agreed governance condition in an employment or operating agreement.
The purpose is not to judge health.
It is to make sure the organization knows what happens next.
The distinction that matters: health privacy vs continuity transparency
This is the key idea.
Health privacy should remain private. Continuity architecture should be transparent.
Those two principles are not in conflict.
In fact, separating them may be the cleanest way to avoid the worst version of executive health programs — where companies become too involved in personal medical information — while still acknowledging the obvious reality that leadership capacity matters.
The organization needs to know who can act.
It does not need to know the leader’s LDL cholesterol.
The board needs to know which decisions transfer during an absence.
It does not need access to the leader’s MRI.
The family needs clarity about authority.
It does not need a dashboard of private biomarkers.
That is a much healthier boundary.
What this means now
For founders, CEOs, and family enterprises, I would add one private annual question to the usual succession discussion:
If my usable capacity dropped for 90 days, what would break first?
Then solve that problem before biology forces the issue.
That may mean documenting decision rights, transferring institutional knowledge, developing a second leader, reducing founder-only approvals, defining a temporary delegation process, or privately addressing a health factor that is narrowing capacity.
None of this predicts illness.
None of it guarantees longevity.
And none of it replaces conventional succession planning.
It simply acknowledges that enterprise continuity and human continuity are connected.
The larger idea
Family offices are built to preserve optionality across generations.
But optionality depends on more than capital.
It depends on capable people being able to use that capital, exercise judgment, maintain relationships, and transfer knowledge before an emergency makes the decision for them.
The mature version of “Healthspan Is Family Capital” is not that the family should medicalize leadership.
It is that the family should remove unnecessary fragility from the system while protecting the dignity and privacy of the person at its center.
A good succession plan answers: Who leads next?
A good continuity plan answers: How do we keep functioning when conditions change?
A biological continuity plan adds one more question:
How do we protect the human capacity on which all the other plans depend?